Studies how clonal hematopoiesis may relate to inflammation in people with heart failure
Observes adults with heart failure to study blood changes linked to inflammation.
Plain-language title generated from the registry record
Registry title: Clonal Hematopoiesis of Indeterminate Potential in Heart Failure.
Key facts
- Where
- Bergamo, ItalySee the 2 sites
Where in Italy
- Asst Papa Giovanni Xxiii - Dip. Di CardiologiaBergamo, ItalyTaking people
- ATS BERGAMO Agenzia di Tutela della SaluteBergamo, ItalyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- Trial code
- NCT06626685
- Record updated
- 10 July 2026
- Original description
This study is part of the Rico Macro-Project, a multidisciplinary research program promoted by FROM in collaboration with the ASST-PG23 and ATS Bergamo, aiming to investigate the role of clonal hematopoiesis on inflammation, studying in depth the mechanisms underlying the inflammatory process to determine their correlation with some important pathologies in different clinical fields (Hematology, Cardiology, Neurology, Pneumology, Gastroenterology, and Diabetology, etc.). In this context, the prospective observational study RICO-HF is developed.Read full original descriptionShow less
Clonal Hematopoiesis of Indeterminate Potential in Heart Failure - RICO-HF.
This study is part of the Rico Macro-Project, a multidisciplinary research program promoted by FROM in collaboration with the ASST-PG23 and ATS Bergamo, aiming to investigate the role of clonal hematopoiesis on inflammation, studying in depth the mechanisms underlying the inflammatory process to determine their correlation with some important pathologies in different clinical fields (Hematology, Cardiology, Neurology, Pneumology, Gastroenterology, and Diabetology, etc.). In this context, the prospective observational study RICO-HF is developed.
The RICO HF is the first project focused on CHIP and inflammation in the area of Cardiology, specifically in HF.
Inclusion: consecutive patients admitted to the Cardiology Unit of the ASST Papa Giovanni XXIII Hospital, Bergamo for acute HF and patients attending the outpatient HF clinic of the same hospital for chronic HF; age >18 years; written informed consent.
Exclusion: chronic therapy with anti-inflammatories, steroids, immunomodulators, immunosuppressants, chemotherapeuthic agents; previous heart transplant; cardiogenic shock or cardiac arrest; recent acute coronary syndrome (<3 months); current acute infection requiring specific treatment; primary myelodysplastic syndromes; malignant cancers; overt MPNs; non-cardiovascular co-morbidity reducing life expectancy to < 1 year; any factor precluding 1-year follow-up.